Medtronic’s VenaSeal Closure System Receives FDA Approval For Treating Chronic Venous Disease
Executive Summary
Adding to its product portfolio for treating superficial venous reflux, Medtronic has now received US approval for a more minimally invasive device, the VenaSeal closure system, which uses adhesive injections to seal the diseased vein in select patients with chronic venous insufficiency. Superficial venous reflux can lead to symptomatic varicose veins.
You may also be interested in...
FDA Approves Medtronic’s VenaSeal To Treat Venous Reflux
VenaSeal was developed by Sapheon Inc., which Covidien acquired in the summer of 2014 shortly after it announced plans to merge with Medtronic.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.